Ascendia Pharmaceuticals, a specialty pharmaceutical contract development and manufacturing organisation (CDMO) in North America, announced on Thursday that it has been added to the 2023 Inc. 5000 list.

The company has been added to the list for the fourth consecutive year. Ascendia Pharmaceuticals is ranked number 1998 in the 2023 list based on its 280% three-year revenue growth.

Ascendia founder and CEO Jim Huang, PhD, said, 'The Inc. 5000 is recognition that clearly indicates the talent, commitment, and passion of our talented team. Being named to the list for four consecutive years is an accomplishment but the true achievement for Ascendia is that we have partnered with pharmaceutical/biotech companies to help develop and deliver drugs that will better treat society.'